TTRX news

Turn Therapeutics Inc. announced CEO Bradley Burnam and Executive Clinical Lead Dr. Stephen M. Hahn will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 23, 2026.

Turn Therapeutics named former CDC head Dr. Robert Redfield its Chief Scientific Officer to oversee clinical strategy, following interim data for its GX-03 treatment.

Turn Therapeutics revealed the final adaptive Stage 2 design for its atopic dermatitis drug GX-03 after observing clinically meaningful efficacy across various disease severities. The trial expansion and use of an FDA-recognized statistical method significantly strengthen the outlook for regulatory …

Turn Therapeutics announced interim analysis results from its Phase 2 trial of GX-03 for moderate-to-severe atopic dermatitis, showing 92.6% of treated subjects achieved 50% eczema severity reduction within 4 weeks with no serious adverse events. The positive efficacy and safety findings led the com…

Turn Therapeutics announced publication of a peer-reviewed study in the Journal of Dermatological Treatment demonstrating GX-03's efficacy in an IL-36-associated inflammatory dermatitis model with statistically significant disease severity reduction. The publication supports the company's Phase 2 de…

Turn Therapeutics announced its CEO Bradley Burnam will present at the Jefferies Global Healthcare Conference on June 4, 2026. The company's lead candidate GX-03 is in Phase 2 trials for atopic dermatitis with topline results expected mid-2026.